Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in
particular, the effects on plasma changes in triglycerides.
Secondary Objectives:
The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48;
free fatty acid, lipoprotein distribution, cholesterol, and low-density lipoprotein (LDL)
oxidation.
The effect of lixisenatide on chronic low-grade inflammation present in non-insulin dependent
diabetes mellitus (NIDDM) and obesity.
The effect of lixisenatide on microvascular dysfunction. To evaluate the effect of
lixisenatide on postprandial plasma glucose, insulin and C-peptide and glucagon.